AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixekizumab
Description: Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brodalumab
Description: Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guselkumab
Description: Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risankizumab
Description: Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tildrakizumab
Description: Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimekizumab
Description: Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.
Study NCT04663191 — intervention group
Intervention type: PROCEDURE
Intervention: anatomical resection
Description: Anatomical resection with systematic lymph-node dissection
Study NCT01290159 — intervention group
Intervention type: OTHER
Intervention: heat tolerance test (HTT)
Description: An exercise-heat test,which consists of 120 min exposure to walking on a treadmill (5km/h; 2% grade) under conditions of 40oC and 50% rh.
Study NCT03198676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP-001 6.4 mg
Description: 6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
Study NCT03198676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP-001 6.4 mg
Description: 6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
Study NCT03198676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP-001 3.2 mg
Description: 3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
Study NCT03198676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
Study NCT02057887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10660A
Study NCT02057887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: 180 mcg Pegasys SC once weekly
Study NCT04087915 — intervention group
Intervention type: DRUG
Intervention: Evolocumab
Description: Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference
Study NCT04426227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discovery learning
Description: A phase of discovery learning guided by novice operators themselves
Study NCT04238650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB02 (Bevacizumab Biosimilar)
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
Study NCT04238650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU approved Avastin®
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
Study NCT01221610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux DRB
Study NCT01221610 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA (POBA)
Study NCT04607057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition Solutions
Description: * Day0 : fasting(NPO) + crystalloid fluid~* POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~* POD#2 : Semifluid diet (SFD) + crystalloid fluid~* POD#3 : Semifluid diet (SFD) + PN~* POD#4-7: Soft blended diet (SBD) + PN
Study NCT01688557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)
Description: NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.
Study NCT01688557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional colonoscopy (Olympus CF-H180DL)
Description: Conventional colonoscopy performed without innovative techniques used in experimental arm.
Study NCT01050465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health information prescription
Description: Patients randomized to the email arm will receive a health information prescription via email on a health care topic following their clinic visit. Patients randomized to the paper arm will receive a health information prescription on paper on a health care topic following their clinic visit.
Study NCT02744651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA
Description: Please note the text in section Arm description
Study NCT00999817 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: reference [dextromethorphan]
Description: single 30 mg oral dose
Study NCT00999817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test [PF-00299804 + dextromethorphan]
Description: single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
Study NCT00980447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMN-0501
Description: 2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart
Study NCT00980447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMN-0501
Description: 2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart
Study NCT00980447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMN-0501
Description: 2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
Study NCT01822626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational counseling
Description: A family pediatrician-lead counselling was offered to children assigned to the intervention group. The counselling program consisted of 5 motivational interviews based on Stages of Change Theory. Child and family always had to leave the meeting having agreed two objectives, one concerning food and one physical activity improvements, clearly defined and achievable. During each subsequent interview was assessed the degree of achievement of the objectives of the previous meeting. Based on the assessment the objective could be reinforced or redefined. After each change the objectives were recorded.
Study NCT02023294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Convetional laparoscopic Sleeve Gastrectomy
Description: Convetional laparoscopic sleeve gastrectomy using 5 ports (incisions) in the abdominal wall
Study NCT02023294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SILS Sleeve gastrectomy
Description: Single incision Sleeve gastrectomy using only one port (incision) on the abdominal wall assisted by an special Traction Device for single port surgery (Endograb)
Study NCT04022876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
Study NCT04022876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered IV on Day 1 of every 21-day cycle.
Study NCT02744651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-Endodrill biopsy
Description: Please note the text in section Arm description
Study NCT00654459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Mixture of Berberine, Policosanol, Red Yeast, Placebo
Description: A tablet one a day for 6 weeks
Study NCT00118430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care
Description: Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.
Study NCT00118430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressants
Description: Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
Study NCT00118430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
Study NCT00171847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT02541292 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational
Study NCT00171847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Letrozole
Study NCT01332747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safoof e muhazzil
Description: drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~to be given in a dosage of 5 gms twice daily
Study NCT01798472 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cemented hemiarthroplasty
Description: Patients aged 80 years and older operated with an cemented hemiarthroplasty. Fixation of the wedge-shaped, polished ChromCobalt steel femoral stem to host bone by use of PolyMetylMetAcrylat bone cement. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
Study NCT01798472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reverse hybrid total hip arthroplasty
Description: Patients aged 65 to 79 years operated with an uncemented femoral component combined with cemented acetabular cup. The femoral stem is fixed to the host bone by press-fit technique. We use a tapered, proximally hydroxyapatite coated, titanium stem. The acetabular cup is fixed to the host bone with bone cement. We use an all-polyethylene design. Bone cement consists of PolyMetylMetAcrylat.
Study NCT01798472 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cemented total hip arthroplasty
Description: Patients aged 65 to 79 years operated with a cemented femoral stem combined with a cemented acetabular cup. Femoral and acetabular component are fixed to the host bone by use of bone cement. The femoral stem is a polished, wedge-shaped design made of ChromCobalt steel. The acetabular cup is fixed to the host bone with bone cement.The acetabular cup an all-polyethylene design. Bone cement consists of PolyMetAcrylat.
Study NCT01798472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uncemented hemiarthroplasty
Description: Patients aged 80 years and older are randomized to uncemented hemiarthroplasty. Fixation of the tapered, proximally hydroxyapatite coated, titanium stem to the host bone by press-fit-technique. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
Study NCT01061762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stick To It
Description: 3-counseling session adherence intervention tailored for people with poor literacy skills
Study NCT01061762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard medication adherence counseling
Description: 3 counseling sessions for adherence improvement derived from standard behavioral approaches.
Study NCT01061762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Counseling
Description: 3-session of health improvement counseling to serve as an attention control.
Study NCT00787527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolinza (vorinostat)
Description: Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
Study NCT00787527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 by vein over 1 hour on Day 1 of 21 day cycle
Study NCT00787527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
Study NCT00787527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
Study NCT00787527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
Study NCT03331393 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study NCT01728610 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic (Active high)
Description: Higher dose of probiotic supplement
Study NCT01728610 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic (Active low)
Description: Lower dose of probiotic supplement
Study NCT01728610 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00723489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Yellow Fever Vaccine (YFV-17D)
Study NCT00723489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YFV-17D Placebo
Study NCT02399189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-MT followed by auto-HSCT
Description: Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
Study NCT01332747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compressed tablet of safoof e muhazzil
Description: drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily
Study NCT01332747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: atorvastatin 10 mgs once daily
Study NCT00547521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
Study NCT00547521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
Study NCT00629473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-0052 on Days 1, 8, 15 every 28 days
Description: NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
Study NCT00629473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-0052 on Days 1, 4, 8, 11 every 21 days
Description: NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
Study NCT00629473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg oral or IV day before and day after NPI-0052 dosing.
Study NCT04384627 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Delineating the GTV according to the pretreatment or post-IC tumor extension
Description: Delineating the GTV according to the pretreatment or post-IC tumor extension
Study NCT02090205 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-ventilation during CPB
Description: Patients that will not be ventilated during cardio-pulmonary bypass
Study NCT02090205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation with CPAP
Description: These patients will receive CPAP (at least 5 cmH2O and FiO2 50%-80%)
Study NCT00622479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib will be administered at 400mg BID for a 28 day cycle.
Study NCT03432741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given intralesionally
Study NCT03432741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given intralesionally
Study NCT03432741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given intralesionally
Study NCT03432741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given intralesionally
Study NCT02090205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation with 5 act/minute
Description: These patients will receive mechanical ventilation (5 acts/minute) during CPB
Study NCT02090205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous Positive Air Pressure, applicated during cardio-pulmonary bypass
Study NCT03432741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET
Study NCT04384627 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Delineating the GTV according to the pretreatment or post-IC tumor extension
Description: Delineating the GTV according to the pretreatment or post-IC tumor extension
Study NCT02090205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilator: 5 act/minute
Description: Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
Study NCT01115309 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: XprESS Balloon Device
Description: Sinus dilation completed with the XprESS Balloon Device with or without additional endoscopic sinus surgery procedures (dilation of the frontal recesses, maxillary ostia, and/or sphenoid sinus ostia).
Study NCT03648749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-to-noise feedback
Description: A target speech-to-noise level is specified and feedback about achievement of the target level is provided.
Study NCT01427400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin-A
Description: 100 Units diluted in 25cc saline
Study NCT01427400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Dispensed in a 25cc syringe